Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents

References

• Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15:312–322.
   PubMed Web of Science ®Google Scholar
• Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130:1181–1188.
   PubMed Web of Science ®Google Scholar
• Thomas MR, de Groot R, Scully MA, et al. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. EBioMedicine. 2015;2:942–952.
   PubMed Web of Science ®Google Scholar
• Sinkovits G, Szilágyi Á, Farkas P, et al. Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura. Front Immunol. 2018;9:1646.
   PubMed Web of Science ®Google Scholar
• Hassan A, Iqbal M, George JN. Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. Am J Hematol. 2019;94(6):ajh.25466.
   PubMed Web of Science ®Google Scholar
• Scheiflinger F, Knöbl P, Trattner B, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241–3243.
   PubMed Web of Science ®Google Scholar
• Fuchs TA, Hovinga JAK, Schatzberg D, et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120:1157–1164.
   PubMed Web of Science ®Google Scholar
• Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology. 2018;2018:530–538.
   PubMedGoogle Scholar
• Bugarin-Estrada E, Gómez-De León A, López-García YK, et al. Clinical presentation in thrombotic thrombocytopenic purpura: real-world data from two Mexican institutions. J Clin Apher. 2018;33:645–653.
   PubMed Web of Science ®Google Scholar
• Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1:590–600.
   PubMed Web of Science ®Google Scholar
• Patschan D, Witzke O, Dührsen U, et al. Acute myocardial infarction in thrombotic microangiopathies—clinical characteristics, risk factors and outcome. Nephrol Dial Transplant. 2006;21:1549–1554.
   PubMed Web of Science ®Google Scholar
• Bendapudi PK, Li A, Hamdan A, et al. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA research collaborative. Br J Haematol. 2015;171:836–844.
   PubMed Web of Science ®Google Scholar
• Ayanambakkam A, Kremer Hovinga JA, Vesely SK, et al. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20%. Am J Hematol. 2017;92:E644–E646.
   PubMed Web of Science ®Google Scholar
• Mackie I, Langley K, Chitolie A, et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost. 2013;109:488–496.
   PubMed Web of Science ®Google Scholar
• Mancini I, Valsecchi C, Lotta L, et al. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost. 2014;112:297–303.
   PubMed Web of Science ®Google Scholar
• Binder NB, Griffiths M, Vetr H. A rapid and simple assay for the determination of adamts-13 activity. Blood. 2016;129(22):1399.
   Web of Science ®Google Scholar
• Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836–2846.
   PubMed Web of Science ®Google Scholar
• Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. Morty RE, editor. PLoS One. 2010;5:e10208.
   PubMed Web of Science ®Google Scholar
• Bentley MJ, Wilson AR, Rodgers GM. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort. Vox Sang. 2013;105:313–318.
   PubMed Web of Science ®Google Scholar
• Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4:e157–e164.
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in thrombotic microangiopathies: unraveling Ariadne’s thread into the labyrinth of complement therapeutics. Front Immunol. 2019;10:337.
   PubMed Web of Science ®Google Scholar
• Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment. Blood. 1977;50:413–418.
   PubMed Web of Science ®Google Scholar
• Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–397.
   PubMed Web of Science ®Google Scholar
• Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. N Engl J Med. 1991;325:398–403.
   PubMed Web of Science ®Google Scholar
• Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore). 2003;82:27–38.
   PubMed Web of Science ®Google Scholar
• Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin Apher. 2016;31:149–338.
   PubMed Web of Science ®Google Scholar
• Patriquin CJ, Clark WF, Pavenski K, et al. How we treat thrombotic thrombocytopenic purpura: results of a Canadian TTP practice survey. J Clin Apher. 2017;32:246–256.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion. 2007; 071121030748006-???. DOI:10.1111/j.1537-2995.2007.01530.x
   Web of Science ®Google Scholar
• Soucemarianadin M, Benhamou Y, Delmas Y, et al. Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA reference center experience. Eur J Haematol. 2016;97:183–191.
   PubMed Web of Science ®Google Scholar
• Willis MS, Bandarenko N. Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Semin Thromb Hemost. 2005;31:700–708.
   PubMed Web of Science ®Google Scholar
• Bandarenko N, Brecher ME. United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher. 1998;13:133–141.
   PubMed Web of Science ®Google Scholar
• Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med. 1995;122:569.
   PubMed Web of Science ®Google Scholar
• Staley EM, Cao W, Pham HP, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica. 2019;104:166–175.
   PubMed Web of Science ®Google Scholar
• Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3:1512–1518.
   PubMed Web of Science ®Google Scholar
• Cataland SR, Scully MA, Paskavitz J, et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol. 2011;86:87–89.
   PubMed Web of Science ®Google Scholar
• Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122:2023–2029.
   PubMed Web of Science ®Google Scholar
• Mancini I, Pontiggia S, Palla R, et al. Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP registry. Thromb Haemost. 2019;119:695–704.
   PubMed Web of Science ®Google Scholar
• Lin Q, Fan L, Huang H, et al. Combination of fresh frozen plasma and cryosupernatant plasma for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single institution experience. BioMed Res Int. 2019;2019:1–6.
   Web of Science ®Google Scholar
• Swart L, Schapkaitz E, Mahlangu JN. Thrombotic thrombocytopenic purpura: a 5-year tertiary care centre experience. J Clin Apher. 2019;34:44–50.
   PubMed Web of Science ®Google Scholar
• Korkmaz S, Keklik M, Sivgin S, et al. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2013;48:353–358.
   PubMed Web of Science ®Google Scholar
• Jacob S, Dunn BL, Qureshi ZP, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:845–853.
   PubMed Web of Science ®Google Scholar
• Wiernek SL, Jiang B, Gustafson GM, et al. Cardiac implications of thrombotic thrombocytopenic purpura. World J Cardiol. 2018;10:254–266.
   PubMed Web of Science ®Google Scholar
• Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009;49:873–887.
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Liu C, Grossman BJ. Platelet transfusion in thrombotic thrombocytopenic purpura. Vox Sang. 2015;109:168–172.
   PubMed Web of Science ®Google Scholar
• Cataland S, Yang S, Masias Castanon C, et al. A prospective, randomized study of cyclosporine or corticosteroids as an adjunct to plasma exchange for the treatment of thrombotic thrombocytopenic purpura. Blood. 2016;128:133.
   Web of Science ®Google Scholar
• Som S, Deford CC, Kaiser ML, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion. 2012;52:2525–2532.
   PubMed Web of Science ®Google Scholar
• Balduini CL, Gugliotta L, Luppi M, et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89:591–596.
   PubMed Web of Science ®Google Scholar
• Ziman A, Mitri M, Klapper E, et al. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution’s experience and review of the literature. Transfusion. 2005;45:41–49.
   PubMed Web of Science ®Google Scholar
• Nosari A, Redaelli R, Caimi TM, et al. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2009;84:313–314.
   PubMed Web of Science ®Google Scholar
• Cataland SR, Jin M, Lin S, et al. Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol. 2007;139:486–493.
   PubMed Web of Science ®Google Scholar
• Beloncle F, Buffet M, Coindre J-P, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience. Transfusion. 2012;52:2436–2444.
   PubMed Web of Science ®Google Scholar
• Gutterman LA, Kloster B, Tsai H-M. Rituximab Therapy for Refractory Thrombotic Thrombocytopenic Purpura. Blood Cells Mol Dis. 2002;28:385–391.
   PubMed Web of Science ®Google Scholar
• Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746–1753.
   PubMed Web of Science ®Google Scholar
• Dane K, Chaturvedi S. Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology. 2018;2018:539–547.
   PubMedGoogle Scholar
• Page EE, Kremer Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016;127:3092–3094.
   PubMed Web of Science ®Google Scholar
• Westwood J-P, Webster H, McGuckin S, et al. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11:481–490.
   PubMed Web of Science ®Google Scholar
• George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/Hemostasis clinical trials network with a systematic review of rituximab therapy for immune mediated disorders. J Clin Apher. 2006;21:49–56.
   PubMed Web of Science ®Google Scholar
• Masias C, Cataland SR. Novel therapies in thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost. 2018;2:19–26.
   PubMed Web of Science ®Google Scholar
• Coppo P, Froissart A. French reference center for thrombotic microangiopathies. Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Hematol Am Soc Hematol Educ Program. 2015;2015:637–643.
   PubMedGoogle Scholar
• McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:1201–1208.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119:3691–3697.
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90:494–500.
   PubMed Web of Science ®Google Scholar
• Goshua G, Gokhale A, Hendrickson JE, et al. Cost effectiveness of rituximab as adjunctive therapy in reducing apheresis procedures and hospital length of stay in relapsed thrombotic thrombocytopenic purpura. Blood. 2018;132:3814.
   Web of Science ®Google Scholar
• Vazquez-Mellado A, Pequeño-Luévano M, Cantu-Rodriguez OG, et al. More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Hematology. 2016;21:311–316.
   PubMed Web of Science ®Google Scholar
• Chen H, Fu A, Wang J, et al. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45:1253–1260.
   PubMed Web of Science ®Google Scholar
• Sadler JE, Muia J, Dolatshahi L, et al. Efficacy of adjuvant low dose rituximab and plasma exchange for acquired TTP with severe ADAMTS13 deficiency — results of the ART study. Blood. 2018;132:374.
   Web of Science ®Google Scholar
• Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–335.
   PubMed Web of Science ®Google Scholar
• Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451–461.
   PubMed Web of Science ®Google Scholar
• Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apheresis. 2008;23:151–156.
   PubMed Web of Science ®Google Scholar
• Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol. 2009;84:418–421.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Heit JA, Pruthi RK, et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol. 2009;83:365–372.
   PubMed Web of Science ®Google Scholar
• de la Rubia J, Moscardó F, Gómez MJ, et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci. 2010;43:299–303.
   PubMed Web of Science ®Google Scholar
• Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center. Crit Care Med. 2012;40:104–111.
   PubMed Web of Science ®Google Scholar
• Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125:3860–3867.
   PubMed Web of Science ®Google Scholar
• Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112:11–18.
   PubMed Web of Science ®Google Scholar
• Hie M, Gay J, Galicier L, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124:204–210.
   PubMed Web of Science ®Google Scholar
• Jestin M, Benhamou Y, Schelpe A-S, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132:2143–2153.
   PubMed Web of Science ®Google Scholar
• Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008;141:651–658.
   PubMed Web of Science ®Google Scholar
• George JN. The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Adv. 2018;2:1510–1516.
   PubMed Web of Science ®Google Scholar
• Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest. 2011;121:593–603.
   PubMed Web of Science ®Google Scholar
• Tersteeg C, Roodt J, Van Rensburg WJ, et al. N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood. 2017;129:1030–1038.
   PubMed Web of Science ®Google Scholar
• Li GW, Rambally S, Kamboj J, et al. Treatment of refractory thrombotic thrombocytopenic purpura with N -acetylcysteine: a case report. Transfusion. 2014;54:1221–1224.
   PubMed Web of Science ®Google Scholar
• Cabanillas G, Popescu-Martinez A. N-acetylcysteine for relapsing thrombotic thrombocytopenic purpura. Am J Ther. 2016;23:e1277–e1279.
   PubMed Web of Science ®Google Scholar
• Shortt J, Opat SS, Wood EM. N -Acetylcysteine for thrombotic thrombocytopenic purpura: is a von Willebrand factor-inhibitory dose feasible in vivo? Transfusion. 2014;54:2362–2363.
   PubMed Web of Science ®Google Scholar
• Acedillo RR, Govind M, Kashgary A, et al. Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura. BMJ Case Rep. 2016;2016:bcr2016215491.
   PubMedGoogle Scholar
• Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368:90–92.
   PubMed Web of Science ®Google Scholar
• Sorvillo N, Pos W, van den Berg LM, et al. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood. 2012;119:3828–3835.
   PubMed Web of Science ®Google Scholar
• Subklewe M, Sebelin-Wulf K, Beier C, et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol. 2007;68:147–155.
   PubMed Web of Science ®Google Scholar
• Eskazan AE. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Ann Hematol. 2016;95:1751–1756.
   PubMed Web of Science ®Google Scholar
• Allanby KD, Huntsman RG, Sacker LS. Thrombotic microangiopathy. Recovery of a case after heparin and magnesium therapy. Lancet. 1966;287:237–239.
   Google Scholar
• Dong J, Cruz M, Aboulfatova K, et al. Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost. 2008;99:586–593.
   PubMed Web of Science ®Google Scholar
• Ravn HB, Vissinger H, Kristensen SD, et al. Magnesium inhibits platelet activity–an in vitro study. Thromb Haemost. 1996;76:88–93.
   PubMed Web of Science ®Google Scholar
• Shechter M, Merz CNB, Rude RK, et al. Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. Am Heart J. 2000;140:212–218.
   PubMed Web of Science ®Google Scholar
• Nadler JL, Malayan S, Luong H, et al. Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care. 1992;15:835–841.
   PubMed Web of Science ®Google Scholar
• Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012;120:3603–3610.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511–522.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15:1448–1452.
   PubMed Web of Science ®Google Scholar
• Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–346.
   PubMed Web of Science ®Google Scholar
• Mai Falk J, Scharrer I. Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse. Transfusion. 2016;56:2819–2823.
   PubMed Web of Science ®Google Scholar
• Bettoni G, Palla R, Valsecchi C, et al. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10:1556–1565.
   PubMed Web of Science ®Google Scholar
• Schiviz A, Wuersch K, Piskernik C, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119:6128–6135.
   PubMed Web of Science ®Google Scholar
• Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol. 2003;120:821–824.
   PubMed Web of Science ®Google Scholar
• Scully M, Knöbl P, Kentouche K, et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017;130:2055–2063.
   PubMed Web of Science ®Google Scholar
• Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost. 2011;9:936–944.
   PubMed Web of Science ®Google Scholar
• Tersteeg C, Schiviz A, De Meyer SF, et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2015;35:2336–2342.
   PubMed Web of Science ®Google Scholar
• Plaimauer B, Schiviz A, Kaufmann S, et al. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13. J Thromb Haemost. 2015;13:2053–2062.
   PubMed Web of Science ®Google Scholar